Superior accuracy of mid-regional proadrenomedullin for mortality prediction in sepsis with varying levels of illness severity

Annals of Intensive Care

Volumn 7, Issue 1, 2017, Pages

  Andaluz Ojeda, David ^a   Nguyen, H Bryant ^b   Meunier Beillard, Nicolas ^c   Cicuéndez, Ramón ^a   Quenot, Jean Pierre ^c   Calvo, Dolores ^a   Dargent, Auguste ^c   Zarca, Esther ^a   Andrés, Cristina ^a   Nogales, Leonor ^a   Eiros, Jose María ^d   Tamayo, Eduardo ^a   Gandía, Francisco ^a   Bermejo Martín, Jesús F ^a   Charles, Pierre Emmanuel ^c  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HÔPITAL DU BOCAGE   (France)

^d UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Biomarkers; Mortality; MR proADM; Sepsis; SOFA

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; LACTIC ACID; MID REGIONAL PROADRENOMEDULLIN; PROADRENOMEDULLIN; PROCALCITONIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HOSPITAL MORTALITY; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; MIDDLE AGED; MORTALITY RATE; MORTALITY RISK; MULTIPLE ORGAN FAILURE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SURVIVAL ANALYSIS;

EID: 85011995292     PISSN: None     EISSN: 21105820     Source Type: Journal    
DOI: 10.1186/s13613-017-0238-9     Document Type: Article

References (25)

1. Vincent J-L. Clinical sepsis and septic shock—definition, diagnosis and management principles. Langenbecks Arch Surg Dtsch Ges Für Chir. 2008;393:817–24.
2. Jean-Baptiste E. Cellular mechanisms in sepsis. J Intensive Care Med. 2007;22:63–72.
3. Hoyert DL, Xu J. Deaths: preliminary data for 2011. Natl Vital Stat Rep Cent Dis Control Prev Natl Cent Health Stat Natl Vital Stat Syst. 2012;61:1–51.
4. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European society of intensive care medicine. Intensive Care Med. 1996;22:707–10.
5. Vincent J-L, Opal SM, Marshall JC. Ten reasons why we should NOT use severity scores as entry criteria for clinical trials or in our treatment decisions. Crit Care Med. 2010;38:283–7.
6. Pierrakos C, Vincent J-L. Sepsis biomarkers: a review. Crit Care Lond Engl. 2010;14:R15.
7. Hirata Y, Mitaka C, Sato K, Nagura T, Tsunoda Y, Amaha K, et al. Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. J Clin Endocrinol Metab. 1996;81:1449–53.
8. Müller-Redetzky HC, Will D, Hellwig K, Kummer W, Tschernig T, Pfeil U, et al. Mechanical ventilation drives pneumococcal pneumonia into lung injury and sepsis in mice: protection by adrenomedullin. Crit Care Lond Engl. 2014;18:R73.
9. Pugin J. Adrenomedullin: a vasodilator to treat sepsis? Crit Care Lond Engl. 2014;18:152.
10. Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an adrenomedullin precursor fragment in plasma of sepsis patients. Peptides. 2004;25:1369–72.
11. Huang DT, Angus DC, Kellum JA, Pugh NA, Weissfeld LA, Struck J, et al. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest. 2009;136:823–31.
12. Albrich WC, Dusemund F, Rüegger K, Christ-Crain M, Zimmerli W, Bregenzer T, et al. Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC Infect Dis. 2011;11:112.
13. Krüger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T, et al. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med. 2010;182:1426–34.
14. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest. 2009;136:e28.
15. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801–10.
16. Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Müller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care Lond Engl. 2005;9:R816–24.
17. Suberviola B, Castellanos-Ortega A, Ruiz Ruiz A, Lopez-Hoyos M, Santibañez M. Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission. Intensive Care Med. 2013;39:1945–52.
18. Marino R, Struck J, Maisel AS, Magrini L, Bergmann A, Di Somma S. Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis. Crit Care Lond Engl. 2014;18:R34.
19. Christ-Crain M, Morgenthaler NG, Stolz D, Müller C, Bingisser R, Harbarth S, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care Lond Engl. 2006;10:R96.
20. Courtais C, Kuster N, Dupuy A-M, Folschveiller M, Jreige R, Bargnoux A-S, et al. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia. Am J Emerg Med. 2013;31:215–21.
21. Renaud B, Schuetz P, Claessens Y-E, Labarère J, Albrich W, Mueller B. Proadrenomedullin improves risk of early admission to ICU score for predicting early severe community-acquired pneumonia. Chest. 2012;142:1447–54.
22. Guignant C, Voirin N, Venet F, Poitevin F, Malcus C, Bohé J, et al. Assessment of pro-vasopressin and pro-adrenomedullin as predictors of 28-day mortality in septic shock patients. Intensive Care Med. 2009;35:1859–67.
23. Travaglino F, De Berardinis B, Magrini L, Bongiovanni C, Candelli M, Silveri NG, et al. Utility of procalcitonin (PCT) and mid regional pro-adrenomedullin (MR-proADM) in risk stratification of critically ill febrile patients in Emergency Department (ED). A comparison with APACHE II score. BMC Infect Dis. 2012;12:184.
24. Bello S, Lasierra AB, Mincholé E, Fandos S, Ruiz MA, Vera E, et al. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. Eur Respir J. 2012;39:1144–55.
25. Andaluz-Ojeda D, Cicuéndez R, Calvo D, Largo E, Nogales L, Muñoz MF, et al. Sustained value of proadrenomedullin as mortality predictor in severe sepsis. J Infect. 2015;71:136–9.